BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase
| Autor: | Dennis Dong Hwan Kim, Lambert Busque, Suzanne Kamel-Reid, Elena Liew, Anargyros Xenocostas, Igor Novitzky Basso, Mary-Margaret Keating, Lynn Savoie, Taehyung Simon Kim, Brian Leber, Tracy Stockley, Robert Delage, Donna L. Forrest, Pierre Laneuville, Kristjan Paulson, Jeffrey H. Lipton, Isabelle Bence-Bruckler, Eshetu G. Atenafu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Fusion Proteins bcr-abl Recursive partitioning Chronic myeloid leukaemia Real-Time Polymerase Chain Reaction Gastroenterology Tyrosine-kinase inhibitor Bcr abl1 Young Adult Recurrence hemic and lymphatic diseases Internal medicine medicine Biomarkers Tumor Doubling time Humans Treatment Failure Child Protein Kinase Inhibitors Aged business.industry Gene Expression Regulation Leukemic Remission Induction Imatinib Hematology Middle Aged Discontinuation Real-time polymerase chain reaction Leukemia Myeloid Chronic-Phase Imatinib Mesylate Female business medicine.drug |
| Zdroj: | British journal of haematologyReferences. 196(1) |
| ISSN: | 1365-2141 |
| Popis: | The doubling time (DT) of the BCR-ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re-growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present study analyzed monthly DT within six months after imatinib discontinuation in 131 patients. Monthly DT was calculated as x = ln(2)/K, where x is the DT and K is the fold BCR-ABL1 change from the previous value divided by the number of days between each measurement. The optimal DT value was determined as 12·75 days at two months using a recursive partitioning method. The patients were stratified into three groups: the high-risk group (DT12·75 days but0, with rapidly proliferating chronic myeloid leukaemia (CML) cells; n = 26) showed the lowest molecular relapse-free survival (mRFS) of 7·7% at 12 months, compared to 53·6% in the intermediate-risk group (DT≥12·75 days, with slowly proliferating CML cells; n = 16) or 90·0% in the low-risk group (DT≤0, i.e., without proliferating CML cells; n = 71; P 0·001). Monthly assessment of DT helps identify high-risk patients for treatment-free remission failure with an imminent risk of molecular recurrence, and to define low-risk patients who can be spared the frequent monitoring of monthly molecular tests. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text